Naringin inhibited the invasion and migration of glioblastoma U87 MG cells by increasing the expression of tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), thereby decreasing the expression and proteinase activity of MMP-2 and MMP-9 and enhancing the focal adhesion kinase (FAK)/MMPs pathway [138]. The gene discussed is MMP9; the disease is glioblastoma.